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Abstract
Background and Aim: Sinusoidal obstruction syndrome (SOS) is a serious drug-induced
liver injury. However, the pathophysiology of the disease remains unclear. This study in-
vestigated the effects of cilostazol (CZ), a phosphodiesterase III inhibitor, in a monocrota-
line (MCT)-induced rat model of SOS.
Methods: Male Wistar rats were administrated MCT to induce SOS. Rats were divided
into control, MCT, and MCT + CZ groups. In the MCT + CZ group, CZ was administered
at 48 h, 24 h, and 30 min prior to and 8 h and 24 h after MCT administration. The MCT
group was treated with water instead of CZ. At 48 h after MCT administration, blood
and liver samples were collected to assess biochemistry and liver histology. Expression
of rat endothelial cell antigen, CD34, CD41, P-selectin, and caspase-3 in the liver were an-
alyzed. Plasminogen activator inhibitor-1 (PAI-1) in hepatocytes was analyzed using west-
ern blotting and polymerase chain reaction.
Results: In the MCT group, macroscopic ﬁndings showed a dark-red liver surface. Histo-
logical ﬁndings showed sinusoidal dilatation, coagulative necrosis of hepatocytes, and en-
dothelial damage of the central vein. These changes were attenuated in the MCT + CZ
group. Elevated serum transaminase and decreased platelet counts were observed in the
MCT + CZ group compared with those in the MCT group. Treatment with CZ reduced
MCT-induced damage to the liver sinusoidal endothelial cells, inhibited extravasated plate-
let aggregation, and suppressed hepatocyte apoptosis around the central vein. CZ attenu-
ated hepatic PAI-1 protein and mRNA levels.
Conclusions: Cilostazol attenuated MCT-induced SOS by preventing damage to liver si-
nusoidal endothelial cells and extravasated platelet aggregation. Hepatic PAI-1 levels were
suppressed with CZ treatment.
Introduction
Sinusoidal obstruction syndrome (SOS), previously called veno-
occlusive disease,1 is a fatal drug-induced liver injury. Drugs such
as busulfan in hematopoietic stem cell transplantation,2,3
cyclophosphamide in immunosuppression therapy and bone mar-
row transplantation,4 and oxaliplatin in chemotherapy5,6 are
known to cause SOS. The clinical features of SOS include
hyperbilirubinemia, painful hepatomegaly, and weight gain due
to ascites.2,7 These features decrease the hepatic functional re-
serve.8 Prevention and treatment of SOS are necessary to improve
complications following liver surgery; however, an effective strat-
egy for SOS remains to be determined.
Several studies have reported that initial pathophysiological
changes in SOS are possibly the result of drug-induced injury to
liver sinusoidal endothelial cells (LSEC),4,9–16 but mechanisms
after LSEC damage remain unclear. We previously immuno-
stained for CD42b, a platelet surface marker, and observed plate-
lets in contact with hepatocytes, especially in zone 3, in the liver
tissue of a liver transplant recipient with severe SOS. It was sug-
gested that platelets exist in the extravascular space, the space of
Disse, and destruction of hepatocytes were observed.17,18 Because
of a lack of nuclei, platelets are invisible on histological analysis
using hematoxylin and eosin (HE) staining.
We considered that LSEC are injured in the liver of SOS pa-
tients, and platelets that aggregate in the extravascular space,
the space of Disse, play an important role in processes resulting
in SOS. We termed platelet aggregation in the extravascular
space as extravasated platelet aggregation (EPA).17–19 In the cur-
rent study, we hypothesized that to prevent LSEC damage and in-
stead of antiplatelet therapy, anti-EPA therapy is beneﬁcial for
SOS and results in the promotion of liver regeneration. To this
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end, we used a phosphodiesterase (PDE) III inhibitor, which has
a protective effect on LSEC9 and inhibits platelet aggregation, to
investigate the pathophysiology of SOS and the efﬁcacy of PDE-
III inhibitor in the pharmacological prevention of SOS in the liver
of a rat model of SOS.
Methods
Reagents. Monocrotaline (MCT) is a pyrrolizidine alkaloid
found in Crotalaria and was purchased from Wako Pure Chemical
Industries (Osaka, Japan). To prepare a solution of MCT at
20 mg/mL, 1000 mg of MCT was dissolved in 1.0 N HCl, and
the pH was adjusted to 7.4 with 0.5 N NaOH. Phosphate-buffered
saline (pH 7.4) was added to increase the total volume to
50 mL.5,20 Cilostazol (CZ), a PDE-III inhibitor, was provided by
Otsuka Pharmaceutical Co. (Tokyo, Japan) and dissolved in water
with carboxymethyl cellulose sodium salt (Wako Pure Chemicals).
CZ is a speciﬁc inhibitor of PDE-III and has been studied for its
inhibitory effects on platelet aggregation via increased cyclic aden-
osine monophosphate levels.
Animals. Male Wistar rats (230–300 g; Charles River Labo-
ratories, Inc., Japan) were used and had free access to water
and standard laboratory chow. The study was conducted in com-
pliance with the Division for Animal Research Resources,
University of Kanazawa, and experiments and procedures were
approved by the Animal Care and Use Committee, University
of Kanazawa.
Experimental protocol. Rats were randomly divided into
three groups (n = 10 per group): control, MCT, and MCT + CZ.
The protocol is shown in Figure 1. Rats had access to water and
standard laboratory chow ad libitum but were fasted for 12 h be-
fore the administration of MCT (90 mg/kg). In the MCT + CZ
group, 30 mg/kg CZ was administered orally at 48 h, 24 h, and
30 min prior to and 8 and 24 h after administration of MCT. In
the other groups, solvent water was administered orally at the same
time periods. Histopathological changes at 48 h after administra-
tion of MCT in rats are similar to those in human SOS.5,21 Rats
were anesthetized by inhalation of diethyl ether and killed for the
collection of serum from the inferior vena cava and liver tissue.
Macroscopic ﬁndings. A midline incision was made. Tis-
sues were examined for the accumulation of peritoneal ﬂuid and
the color of the liver surface to determine the effects of CZ.
Biochemical analysis. Blood samples were taken, and
white blood cells, hemoglobin, and platelets were counted using
an automated blood cell counter (Celltac α MEK-6458; Nihon
Kohden, Tokyo, Japan). Aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), total bilirubin (T-Bil), direct biliru-
bin, lactate dehydrogenase, and hyaluronic acid (HA) were
measured in the same samples. Measurements were performed
by SRL Inc., Japan.
Histological analysis. Liver tissue was ﬁxed in 10% neu-
tral buffered formalin, embedded in parafﬁn, and cut serially into
4-μm sections. Slides were prepared and stained with HE and
Figure 1 Experimental protocol. Isotonic sodium chloride solution was administered orally instead of MCT in the control group. In all groups, blood
and liver samples were collected at 48 h after either MCT or solvent water treatment. CZ, cilostazol; MCT, monocrotaline.
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evaluated in 10 randomly. To quantify the degree of SOS, histo-
logical changes were determined according to sinusoidal dilata-
tion, coagulative necrosis of hepatocytes, endothelial damage of
the central vein, and sinusoidal hemorrhage.5,21,22 Each of these
features was graded on a 4-point scale: 0 = absent; 1 = mild
(1–30%); 2 = moderate (31–60%); 3 = severe (61–100%). The
total SOS score was calculated as the sum of individual scores.
Immunohistochemistry. For assessment of damage to
LSEC, immunostaining for rat endothelial cell antigen 1 (RECA-
1) (#MCZ-970R; Serotec, Oxford, UK) and CD34 (1:20,
AF4117; R&D Systems, Minneapolis, MN, USA) was performed.
Tissue samples were ﬁxed with 4% paraformaldehyde phosphate
buffer solution for 3 days and embedded in a solution of optimal
cutting temperature compound (Sakura Finetek, Tokyo, Japan),
30% sucrose in phosphate buffer (0.1 M, pH 7.4), and 0.05%
NaN3. Tissue samples were sectioned (6 μm thick) using cryostats
(Thermo Fisher Scientiﬁc, Waltham, MA, USA). For assessment
of platelet aggregation, immunostaining for CD41 antibody
(1:100 orb4832; Biorbyt, Cambridge, UK) and P-selectin (1:50,
ERP1444(2)(B); Abcam, Tokyo, Japan) was performed. For as-
sessment of liver apoptosis, immunostaining for anti-cleaved
caspase-3 antibody (1:100 9661; Cell Signaling Technology, Bev-
erly, MA, USA) was performed.
Reverse transcription quantitative PCR analysis.
Total RNA was extracted from liver tissues using an RNeasy mini
kit (Qiagen, Tokyo, Japan). Residual DNA in isolated total RNA
preparations was removed by treatment with DNase (Qiagen),
and 5 μg RNA was reverse-transcribed using SuperScript reverse
transcriptase (Invitrogen, Carlsbad, CA, USA). Primer sets used
were for plasminogen activator inhibitor-1 (PAI-1) and for glycer-
aldehyde phosphate dehydrogenase as an internal control. Primers
were synthesized by Hokkaido System Science (Hokkaido, Japan).
Real-time polymerase chain reaction (PCR) was performed using
Mx QPCR Systems and Complete QPCR Portfolio (Agilent Tech-
nologies, Santa Clara, CA, USA) according to the manufacturer’s
instructions. All cDNA samples were analyzed in triplicate, and
each run contained a relative standard curve.
Western blotting. Total protein was extracted from liver tis-
sues kept at 80 °C in T-PER tissue protein extraction reagent
(Pierce Biotechnology, Rockford, IL, USA). A ratio of 0.01 g of
tissue to 80 μL T-PER reagent and 0.4 μL protease inhibitor was
mixed and homogenized. Samples were centrifuged and superna-
tant collected for analysis. Samples were separated on 10% sodium
dodecylsulfate–polyacrylamide gel electrophoresis gels and trans-
ferred to polyvinylidene diﬂuoride membranes (Bio-Rad, Hercu-
les, CA, USA). PAI-1 antibody (ab7205; Abcam, Cambridge,
UK) at 1:1000 dilution and β-actin (Sigma-Aldrich, St. Louis,
MI, USA) at 1:10 000 were used as the primary antibodies. The
antibody–antigen complex was detected using a light-capture sys-
tem (Atto, Tokyo, Japan) and a CS analyzer program (Atto).
Statistical analysis. Results are expressed as mean ± stan-
dard deviations. Comparisons between two groups were performed
using Student’s t-tests, as appropriate. A P-value < 0.05 was con-
sidered statistically signiﬁcant. Statistical analyses were performed
using SPSS version 11.0.1 (SPSS Inc., Chicago, IL, USA).
Results
Morphology. At sacriﬁce, macroscopic liver ﬁndings in the
MCT group showed bloody ascites and the liver surface appeared
congested and dark red. These changes were attenuated in the
MCT + CZ group (Fig. 2).
Blood chemistry. The MCT and MCT + CZ groups showed
bloody ascites, but blood cell counts showed no signiﬁcant change
in hemoglobin between the groups (Fig. 3). White blood cell and
platelet counts signiﬁcantly decreased in the MCT group com-
pared with those in the control group. These decreases were sup-
pressed in the MCT + CZ group (Fig. 3). The results of serum
biochemistry tests are shown in Table 1. Serum AST, ALT, T-
Bil, direct bilirubin, and HA in the MCT + CZ group were signif-
icantly lower than those in the MCT group (P = 0.007, P = 0.028,
P = 0.005, P = 0.003, P = 0.010, respectively).
Histopathological ﬁndings. The HE staining of livers
showed sinusoidal dilatation, coagulative necrosis of hepatocytes,
endothelial damage of the central vein, and sinusoidal hemorrhage
in the MCT group. In the MCT + CZ group, these morphological
changes were attenuated (Fig. 4). The results were reﬂected in HE
staining scores for each of these four histological features and the
total SOS score. Scores for the MCT + CZ group were signiﬁ-
cantly lower than those in the MCT group (Table 2).
Figure 2 Macroscopic ﬁndings. (a) Control, (b) monocrotaline, and (c) monocrotaline + cilostazol groups. (b) Accumulation of bloody ascites and the
liver surface appeared dark red. (c) The changes were attenuated.
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Immunohistochemistry. Rat endothelial cell antigen 1 pro-
tein expression in the MCT group was markedly reduced compared
with that in the control group. RECA-1 protein expression in the
MCT + CZ group was comparable with that in the control group
(Fig. 4). There was almost no CD34 expression in the control
group, but CD34-positive areas were signiﬁcantly large in the
MCT group. Administration of CZ attenuated CD34 expression
(Fig. 4). CD41 protein expression in the control group was absent.
In the MCT group, CD41 protein expression was only observed in
contact with hepatocytes, especially in zone 3. These changes were
attenuated in the MCT + CZ group (Fig. 4). P-selectin protein ex-
pression was higher in the MCT group compared with that in the
control group. In the control group, there was partial endothelial
cell staining. In the MCT group, endothelial cells and platelets
around the central vein were stained. In the MCT + CZ group, these
changes decreased (Fig. 4). In the control group, cleaved caspase-3-
labeled cells were absent. Cells positive for cleaved caspase-3 la-
beling in the MCT group were observed at a greater extent in the
MCT group compared with those in the MCT + CZ group (Fig. 4).
PAI-1 expression. Results from reverse transcription quanti-
tative PCR analysis are shown in Figure 5. PAI-1 mRNA expres-
sion in the MCT and MCT + CZ groups were signiﬁcantly higher
than that in the control group (P = 0.003 and P = 0.016, respec-
tively). There was no signiﬁcant difference between the MCT
group and the MCT + CZ group. PAI-1 mRNA in the MCT + CZ
group tended to show a reduction compared with that in the MCT
group. With western blotting, hepatic PAI-1 protein expression in
the MCT group was higher than that in the MCT + CZ group
(Fig. 5).
Discussion
Sinusoidal obstruction syndrome is a drug-induced liver injury
resulting in multi-organ failure and death4 and is mostly associated
with hematopoietic stem cell transplantation,2,3 cyclophosphamide
in immunosuppression therapy for liver transplants,4 and chemo-
therapy such as oxaliplatin.5,6 It is characterized by
hyperbilirubinemia, painful hepatomegaly, and weight gain due
to ascites.2,7 In recent years, increasing numbers of studies have
described the mechanisms behind SOS and suggest that the ﬁrst
pathological change appears in the sinus structure.12,14,23 Reports
suggest that exposure to drug toxins result in swelling and accu-
mulation of LSEC, especially in zone 3.17,24 Subsequent patholog-
ical changes in SOS appear as sinus ﬁbrosis, ﬁbroblast cell
Figure 3 Comparison of hemoglobin (Hb), platelet, and white blood cell (WBC) counts among the three groups. Blood cell counts showed no signif-
icant changes in Hb among the three groups. The platelet count signiﬁcantly decreased in the monocrotaline (MCT) and MCT + cilostazol (CZ) groups.
This decrease was suppressed by the administration of CZ. The WBC count decreased signiﬁcantly in the MCT group. This decrease was suppressed
by the administration of CZ. The WBC count was maintained in the MCT + CZ group. Data are expressed as mean ± standard deviations (n = 10).
*P < 0.01 versus control. **P < 0.01 versus MCT.
Table 1 Serum biochemistry at 48 h after MCT administration
Variable Normal range MCT group MCT + CZ group
AST (IU/L) 71–100 7218 ± 4071 2644 ± 1876*
ALT (IU/L) 30–44 1539 ± 837 760 ± 578*
T-Bil (mg/dL) 0.03–0.05 0.211 ± 0.0836 0.113 ± 0.387*
D-Bil (mg/dL) 0.03–0.04 0.126 ± 0.0538 0.0570 ± 0.0231*
LDH (IU/L) 110–580 5664 ± 3701 3276 ± 2180
HA (ng/dL) 25–60 1011.1 ± 615.7 379.4 ± 144.8*
*P < 0.01 compared with MCT.
Although the administration of monocrotaline (MCT) resulted in consid-
erable elevation in serum aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), total bilirubin (T-Bil), direct bilirubin (D-Bil), lactate
dehydrogenase (LDH), and hyaluronic acid (HA), cilostazol (CZ) resulted
in a noticeable decrease in serum AST, ALT, T-Bil, D-Bil, and HA com-
pared with that in the MCT group. Data are mean ± standard deviations
(n = 10).
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proliferation, degeneration and necrosis of hepatic cells, and colla-
gen accumulation in the extracellular matrix.25–28 It is thought that
such disruption leads to portal hypertension and thrombocytopenia
resulting from hypersplenism. However, the mechanisms behind
these phenomena are not well understood, and an effective method
to prevent and treat SOS is required.
Because platelets have no nucleus, they are not able to be
observed with HE staining upon histological examination. In a
previous study, we noted platelets in contact with hepatocytes of
an immunosuppressed severe SOS patient18 and in liver tissue
treated with oxaliplatin-based chemotherapy.17 In the latter study,
we found that thrombocytopenia occurs before splenomegaly.17
With electron microscopy, we found platelet aggregation in the
space of Disse in an MCT-induced rat model of SOS.19 It was sug-
gested that platelets in the space of Disse are closely associated
with the pathophysiology of SOS. We termed this phenomenon
as EPA.17–19 In the current study, CD41 protein expression, for as-
sessment of platelet aggregation, was observed in contact with he-
patocytes, especially in zone 3, to a greater extent in the MCT
group compared with that in the MCT + CZ group. P-selectin pro-
tein expression, for assessment of activated platelets and damaged
vascular endothelial cells,28 was also greater in the MCT group.
The platelet count signiﬁcantly decreased in the MCT group, yet
this decrease was signiﬁcantly suppressed in the MCT + CZ group
Figure 4 Histological analysis (original magniﬁca-
tion ×400). a–c: HE staining. (a) Control, (b) mono-
crotaline (MCT), and (c) MCT + cilostazol (CZ)
groups. In the control group, there was no evidence
of sinusoidal dilatation, coagulative necrosis of hepa-
tocytes, endothelial damage of the central vein, and
sinusoidal hemorrhage. Administration of MCT in-
duced severe sinusoidal hemorrhage, endothelial
damage of the central vein, and coagulative necrosis
of hepatocytes. Administration of CZ resulted in im-
provements to pathological changes in the liver in-
duced by the administration of MCT. d–f:
Immunohistochemistry of rat endothelial cell anti-
gen (RECA)-1. (d) Control, (e) MCT, and (f) MCT + CZ
groups. Immunohistochemical analysis indicated
that the RECA-1-positive protein expression area in
the control group was widespread and reﬂected nor-
mal sinusoidal lining of endothelial cells. MCT signif-
icantly reduced RECA-1 protein expression
compared with that in the control group. Administra-
tion of CZ resulted in an improvement in the RECA-
1-positive protein expression area. g–i: Immunohis-
tochemistry of CD34. (g) Control, (h) MCT, and (i)
MCT + CZ groups. CD34 protein expression in the
MCT group signiﬁcantly increased compared with
that in the control group. Administration of CZ re-
sulted in reduction of CD34 expression compared
with that in the MCT group. j–l: Immunohistochem-
istry of CD41. (j) Control, (k) MCT, and (l) MCT + CZ
groups. CD41-positive protein expression areas in
the control group were absent. In the MCT group,
CD41 protein expression was observed around the
central vein and in contact with hepatocytes. In the
MCT + CZ group, CD34 expression was weak com-
pared with that in the MCT group. m–o: Immunohis-
tochemistry of P-selectin. (m) Control, (n) MCT, and
(o) MCT + CZ groups. In the control group, expres-
sion of P-selectin was weak. MCT increased the P-
selectin expression area. Administration of CZ re-
sulted in improvements in P-selectin-positive protein
expression areas. p–r: Immunohistochemistry of
caspase-3. (p) Control, (q) MCT, and (r) MCT + CZ
groups. Decreased numbers of cells positive for cas-
pase-3 labeling in the MCT + CZ group was ob-
served compared with that in the MCT group.
Original magniﬁcation ×400.
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(P = 0.004). This suggested that EPA were decreased by CZ ad-
ministration, and SOS is strongly associated with EPA. Several re-
cent studies using MCT-induced rat models of SOS5,21,29,30 have
suggested possibilities for prevention and/or treatment of SOS.
However, these studies did not consider the inﬂuence of platelets
in SOS.
The liver is an efﬁcient regenerative organ. Numerous studies
have examined the mechanisms behind liver regeneration and have
found that regeneration is regulated by the release and activation
of several growth factors. Fibrinolytic factors, such as hepatocyte
growth factor and plasminogen activator, are considered key to
liver regeneration. Several factors that inhibit the ﬁbrinolysis sys-
tem impair liver regeneration.31–35 Among these factors, PAI-1 is
a major physiological negative regulator of ﬁbrinolytic factors. It
is reported that PAI-1 interferes with liver regeneration by sup-
pressing the hepatocyte growth factor.36,37 Recently, PAI-1 ex-
pression was found to be signiﬁcantly elevated in mice with
FOLFOX-induced SOS6 and in a rat model of hepatectomy.36,38
PAI-1 is a well-known endothelial injury marker, but signiﬁcant
amounts of PAI-1 also exist in platelets. Therefore, it was sug-
gested that PAI-1 was released following damage to LSEC
and/or activated platelets.39
We hypothesize that if LSEC are disrupted by drugs, activated
platelets migrate to the space of Disse and aggregate with collagen
produced by hepatic stellate cells. We consider that thrombocyto-
penia occurs at this stage, on the basis of evidence from recent re-
ports.17,19 Sinusoid function depression and hepatic
microcirculation disturbances occur and result in splenomegaly
and thrombocytopenia, and, ultimately, liver dysfunction and he-
patocyte necrosis occur. We suggest that EPA caused by LSEC
damage may play an important role in the development of SOS,
and CZ administration to strengthen LSEC and prevent EPA ap-
peared to improve SOS.
Rat endothelial cell antigen 1 expression reﬂects damage to
LSEC, and the observed reduction in RECA-1 indicated that the
sinusoidal lining had largely disappeared. CD34 expression re-
ﬂects sinusoidal capillarization in liver tissue and can be used to
differentiate between normal and damaged sinusoidal epithe-
lium.28,40,41 In the MCT + CZ group, serum HA was signiﬁcantly
lower (P = 0.039) than that in the MCT group. As there are the
large quantities of HA in LSEC, this increase in HA reﬂects injury
to LSEC.42,43 These results indicated that CZ attenuated MCT-
induced damage to LSEC. CZ administration appeared to attenuate
the macroscopic ﬁndings; elevations in serum AST, ALT, and T-
Bil; and scores for HE staining. These results demonstrate the
Table 2 Sinusoidal obstruction syndrome scores for HE staining at 48 h
after MCT administration
Score (range) MCT MCT + CZ
Sinusoidal dilatation (0–3) 2.7 ± 0.5 1.6 ± 0.7*
Necrosis of hepatocytes (0–3) 2.8 ± 0.4 1.7 ± 0.8*
Endothelial damage of the central vein (0–3) 2.7 ± 0.5 1.7 ± 0.8*
Sinusoidal hemorrhage (0–3) 2.6 ± 0.5 1.7 ± 0.9*
Total score (0–12) 10.8 ± 1.0 6.7 ± 2.1*
*P < 0.01 compared with MCT.
To evaluate the degree of sinusoidal obstruction syndrome, histological
changes of four parameters were examined using a scoring system.
The mean and total score for the monocrotaline (MCT) group were signif-
icantly greater than those in the MCT + cilostazol (CZ) group. Data are
mean ± standard deviations (n = 10).
Figure 5 Expression of plasminogen activator in-
hibitor-1 (PAI-1). (a) Measurement of PAI-1 mRNA.
PAI-1 RNA expression in the monocrotaline (MCT)
and MCT + cilostazol (CZ) groups signiﬁcantly in-
creased compared with that in the control group.
Although there was no signiﬁcant difference, CZ
resulted in a decrease in PAI-1 mRNA expression.
Data are mean ± standard deviations (n = 5). (b)
Western blotting of PAI-1. Western blots of PAI-1
and β-actin in liver tissue. Quantiﬁcation of PAI-1
levels in the MCT group showed overexpression.
A reduction was observed in the MCT + CZ group.
*P < 0.01 versus control.
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effects of CZ on SOS by protecting LSEC and suppression of the
platelet aggregation in the space of Disse.
Plasminogen activator inhibitor-1 expression in the MCT and
MCT + CZ groups was signiﬁcantly higher than that in the control
group, which was barely observed with western blotting and re-
verse transcription quantitative PCR analysis. The MCT + CZ
group showed a decreased tendency compared with the MCT
group. Hepatocyte apoptosis decreased in the MCT + CZ group,
as seen with immunohistochemistry of cleaved caspase-3. We sug-
gest that it might be possible for therapy aimed at protecting LSEC
and preventing EPA with CZ administration to decrease the re-
lease of PAI-1 from LSEC and platelets and improve liver
regeneration.
In the present study, we performed preventive and therapeutic
CZ administration, before and after administration of MCT, and
gave a signiﬁcant improvement in the MCT-induced rat model
of SOS. We used aspirin in the same protocol as an alternative
to CZ, but the favorable results were not observed (data not
shown). It is thought that aspirin can inhibit platelet aggregation
but cannot suppress damage to LSEC. Previous report5 also indi-
cated that pretreatment with PDE-III inhibitor has potential strat-
egy for the prevention of SOS. Actually, once SOS occurs
clinically, the liver damage persists for several months.44 These re-
sults suggest that preventive CZ administration is more effective
for SOS therapy than for therapeutic CZ administration; therefore,
further examination of CZ effect on SOS will be necessary.
Cilostazol, a speciﬁc inhibitor of PDE-III, inhibits platelet ag-
gregation by increasing the cyclic adenosine monophosphate level.
CZ also initiates a decrease in platelet aggregation and secretion in
response to platelet agonists45 and has been reported to suppress
the expression of some adhesion molecules on the endothelium,
such as intercellular adhesion molecule 1 and vascular cell adhe-
sion molecule 1.46 These effects result in the suppression of
leukocyte–endothelial interactions through modulation of eicosa-
noid production.47 Several studies have reported that PDE-III in-
hibitors have protective effects on vasodilator action and
improve vascular smooth muscle cell proliferation.48 In particular,
CZ has protective effects on LSEC by reducing inﬂammation by
up-regulating endothelial nitric oxide synthase (eNOS) in the
liver.49 We found that CZ administration suppressed damage to
LSEC and EPA and contributed to the favorable change in this
MCT-induced rat model of SOS. However, CZ is not yet to be
used for SOS treatment in humans induced by various anti-cancer
chemotherapeutic agents, and the interaction between these drugs
has not become clear. And the effect of CZ on cancer cells remains
unknown. Further examination of CZ is necessary to determine its
full impact before clinical application in patients with SOS.
In a recent study, an MCT-induced rat model of SOS is used to
reﬂect human SOS. It is said that MCT rat model has the same
histological liver characteristics as human SOS as well as similar
symptoms.14 However, this MCT model has some limitations.
For example, the development of SOS in response to MCT is
an acute event occurring within hours, whereas human SOS, in-
duced by drugs such as oxaliplatin, occurs as a consequence of
chronic drug exposure. Because of reasons like these, correla-
tions between the MCT-induced rat model of SOS and human
SOS are exactly unclear. Robinson et al.6 recently reported that
they had developed the ﬁrst reproducible model of chemotherapy
of FOLFOX-induced SOS that reﬂects the pathogenesis of
human SOS. The further investigation of CZ against SOS is re-
quired in other models.
In conclusion, the results of the study indicated an important and
novel role of CZ in this MCT-induced rat model of SOS. Prophy-
lactic administration of CZ prevented EPA resulting from damage
to LSEC. CZ administration also signiﬁcantly decreased PAI-1 ex-
pression. We consider that the result promoted liver regeneration
by inhibiting the coagulation system, and these changes could re-
sult in the suppression of hepatocyte apoptosis. CZ shows thera-
peutic potential for the prevention of SOS.
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